- €890.91m
- €685.25m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.55 | ||
| Price to Tang. Book | 5.21 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -49.56% | ||
| Return on Equity | -145.41% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | n/a | n/a | n/a | n/a | n/a | 1.93 | 15.95 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Abivax SA is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
Directors
- Philippe Pouletty CHM (64)
- Hartmut Ehrlich CEO
- Didier Blondel CFO
- Jerome Denis VPR
- Paul Gineste VPR
- Alexandra Pearce VPR
- Didier Scherrer VRD
- Pierre Courteille VBD
- Sophie Biguenet OTH
- Regina Jehle OTH
- Jamal Tazi OTH
- Kinam Hong DRC
- Antonino Ligresti DRC (84)
- Christian Pierret DRC
- Joy Amundson IND (66)
- Jean-Jacques Bertrand IND (63)
- Corinna Bonsen-thomas IND
- Carol Brosgart IND (70)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- December 4th, 2013
- Public Since
- June 26th, 2015
- No. of Employees
- 40
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
Euronext - Paris- Shares in Issue
- 62,917,479
- Address
- 7-11 Boulevard Haussmann, PARIS, 75009
- Web
- https://www.abivax.com/
- Phone
- +33 153830963
- Contact
- Ligia Vela-Reid
- Auditors
- PricewaterhouseCoopers Audit
Upcoming Events for ABVX
Abivax SA Annual Shareholders Meeting
Half Year 2024 Abivax SA Earnings Release
Similar to ABVX
Abionyx Pharma SA
Euronext - Paris
Acticor Biotech SA
Euronext - Paris
Adocia SA
Euronext - Paris
Biophytis SA
Euronext - Paris
Cellectis SA
Euronext - Paris
FAQ
What is the Abivax SA share price?
As of Today at 19:00 UTC, shares in Abivax SA are trading at €14.16. This share price information is delayed by 15 minutes.
How has the Abivax SA share price performed this year?
Shares in Abivax SA last closed at €14.16 and the price had moved by +2.31% over the past 365 days. In terms of relative price strength the Abivax SA share price has underperformed the FTSE Global All Cap Index by -3.95% over the past year.
What are the analyst and broker recommendations for Abivax SA?
The overall consensus recommendation for Abivax SA is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Abivax SA dividend yield?
Abivax SA does not currently pay a dividend.
Does Abivax SA pay a dividend?
Abivax SA does not currently pay a dividend.
When does Abivax SA next pay dividends?
Abivax SA does not currently pay a dividend.
How do I buy Abivax SA shares?
To buy shares in Abivax SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Abivax SA?
As of the previous close price of €14.16, shares in Abivax SA had a market capitalisation of €890.91m.
Where are Abivax SA shares listed?
Here are the trading details for Abivax SA:
- Country of listing: France
- Exchange: PAR
- Ticker Symbol: ABVX
What kind of share is Abivax SA?
Based on an overall assessment of its quality, value and momentum Abivax SA is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Abivax SA share price forecast for 2024?
The analyst consensus target price for shares in Abivax SA is €21.70. That is 53.25% above the last closing price of €14.16.
Analysts covering Abivax SA currently have a consensus Earnings Per Share (EPS) forecast of -€2.22 for the next financial year.
What is the trend in the Abivax SA share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Abivax SA. Over the past six months, its share price has outperformed the FTSE Global All Cap Index by +41.41%.
As of the last closing price of €14.16, shares in Abivax SA were trading +9.46% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Abivax SA PE Ratio?
The Abivax SA PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at €14.16.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Abivax SA?
Abivax SA's management team is headed by:
- Philippe Pouletty - CHM
- Hartmut Ehrlich - CEO
- Didier Blondel - CFO
- Jerome Denis - VPR
- Paul Gineste - VPR
- Alexandra Pearce - VPR
- Didier Scherrer - VRD
- Pierre Courteille - VBD
- Sophie Biguenet - OTH
- Regina Jehle - OTH
- Jamal Tazi - OTH
- Kinam Hong - DRC
- Antonino Ligresti - DRC
- Christian Pierret - DRC
- Joy Amundson - IND
- Jean-Jacques Bertrand - IND
- Corinna Bonsen-thomas - IND
- Carol Brosgart - IND